Affinity DataKi: 3nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 3nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 4nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 5nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 6nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 10nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 10nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 12nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 16nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 16nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 19nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 20nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 21nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 23nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 26nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 29nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 29nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 32nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 36nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 38nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 42nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 51nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 56nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 68nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 70nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 83nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 83nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Affinity DataKi: 5.93E+3nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: 6.06E+3nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: 9.95E+3nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: 1.27E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: 1.40E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Affinity DataKi: 1.72E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair